Note: This document contains side effect information about cilostazol. Some dosage forms listed on this page may not apply to the brand name Pletal.
Applies to cilostazol: oral tablets.
Warning
- Contraindicated in patients with CHF of any severity.1 2 Decreased survival observed in patients with NYHA class III or IV CHF who received other drugs that inhibit phosphodiesterase (PDE) type 3.1 2
Side effects include:
Headache, diarrhea, abnormal (e.g., loose) stools, dizziness, infection, palpitation, pharyngitis, back pain, nausea, peripheral edema, rhinitis, dyspepsia, increased cough, tachycardia.
For Healthcare Professionals
Applies to cilostazol: oral tablet.
General
The most frequent adverse reactions resulting in discontinuation of therapy were headache, palpitation, and diarrhea.[Ref]
Nervous system
Very common (10% or more): Headache (up to 34%), dizziness (up to 10%)
Frequency not reported: Tinnitus
Postmarketing reports: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma, subdural hematoma
Gastrointestinal
Very common (10% or more): Diarrhea (up to 19%), abnormal stools (up to 15%)
Common (1% to 10%): Dyspepsia, abdominal pain
Frequency not reported: Melena
Postmarketing reports: Gastrointestinal hemorrhage, vomiting, flatulence, nausea[Ref]
Immunologic
Very common (10% or more): Infection (up to 14%)
Postmarketing reports: Anaphylaxis, angioedema, hypersensitivity[Ref]
Respiratory
Very common (10% or more): Rhinitis (up to 12%), pharyngitis (up to 10%)
Frequency not reported: Epistaxis
Postmarketing reports: Pulmonary hemorrhage, interstitial pneumonia[Ref]
Cardiovascular
Very common (10% or more): Palpitation (up to 10%)
Common (1% to 10%): Tachycardia
Frequency not reported: Atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia, left ventricular outflow obstruction
Postmarketing reports: Torsade de pointes, QTc prolongation, angina pectoris, hot flushes, blood pressure increased, subacute stent thrombosis, hypertension[Ref]
Other
Common (1% to 10%): Peripheral edema
Frequency not reported: Fever, generalized edema, malaise
Postmarketing reports: Pain, chest pain[Ref]
Metabolic
Frequency not reported: Anorexia, hyperuricemia
Postmarketing reports: Blood glucose increased, blood uric acid increased[Ref]
Ocular
Frequency not reported: Conjunctivitis, retinal hemorrhage[Ref]
Dermatologic
Frequency not reported: Urticaria
Postmarketing reports: Subcutaneous hemorrhage, pruritus, skin eruptions, Stevens-Johnson syndrome, skin drug eruption, rash[Ref]
Hematologic
Frequency not reported: Anemia
Postmarketing reports: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency[Ref]
Genitourinary
Frequency not reported: Urinary frequency
Postmarketing reports: Hematuria[Ref]
Renal
Frequency not reported: Creatinine increased
Postmarketing reports: BUN increased[Ref]
Psychiatric
Frequency not reported: Insomnia[Ref]
Hepatic
Postmarketing reports: Hepatic dysfunction, abnormal liver function tests, jaundice[Ref]
